151 related articles for article (PubMed ID: 26355665)
1. Concentration-Induced J-Aggregate Formation Causes a Biphasic Change in the Release of trans-Combretastatin A4 Disodium Phosphate from Archaeosomes and the Subsequent Cytotoxicity on Mammary Cancer Cells.
Daswani VP; Ayesa U; Venegas B; Chong PL
Mol Pharm; 2015 Oct; 12(10):3724-34. PubMed ID: 26355665
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
[TBL] [Abstract][Full Text] [Related]
3. Polar Lipid Fraction E from
Ayesa U; Chong PL
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33182284
[TBL] [Abstract][Full Text] [Related]
4. Cholesterol superlattice modulates CA4P release from liposomes and CA4P cytotoxicity on mammary cancer cells.
Venegas B; Zhu W; Haloupek NB; Lee J; Zellhart E; Sugár IP; Kiani MF; Chong PL
Biophys J; 2012 May; 102(9):2086-94. PubMed ID: 22824272
[TBL] [Abstract][Full Text] [Related]
5. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate.
Anderson HL; Yap JT; Miller MP; Robbins A; Jones T; Price PM
J Clin Oncol; 2003 Aug; 21(15):2823-30. PubMed ID: 12807935
[TBL] [Abstract][Full Text] [Related]
6. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
Liu T; Zhang D; Song W; Tang Z; Zhu J; Ma Z; Wang X; Chen X; Tong T
Acta Biomater; 2017 Apr; 53():179-189. PubMed ID: 28167300
[TBL] [Abstract][Full Text] [Related]
7. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging.
Galbraith SM; Maxwell RJ; Lodge MA; Tozer GM; Wilson J; Taylor NJ; Stirling JJ; Sena L; Padhani AR; Rustin GJ
J Clin Oncol; 2003 Aug; 21(15):2831-42. PubMed ID: 12807936
[TBL] [Abstract][Full Text] [Related]
8. Combretastatin A4 phosphate: background and current clinical status.
Young SL; Chaplin DJ
Expert Opin Investig Drugs; 2004 Sep; 13(9):1171-82. PubMed ID: 15330748
[TBL] [Abstract][Full Text] [Related]
9. Enhancing intratumoral biodistribution and antitumor activity of nab-paclitaxel through combination with a vascular disrupting agent, combretastatin A-4-phosphate.
Gao M; Zhang D; Yao N; Jin Q; Jiang C; Zhang J; Wang F
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1187-1194. PubMed ID: 31520101
[TBL] [Abstract][Full Text] [Related]
10. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors.
Dziba JM; Marcinek R; Venkataraman G; Robinson JA; Ain KB
Thyroid; 2002 Dec; 12(12):1063-70. PubMed ID: 12593719
[TBL] [Abstract][Full Text] [Related]
11. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
Galbraith SM; Chaplin DJ; Lee F; Stratford MR; Locke RJ; Vojnovic B; Tozer GM
Anticancer Res; 2001; 21(1A):93-102. PubMed ID: 11299795
[TBL] [Abstract][Full Text] [Related]
12. A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours.
He X; Li S; Huang H; Li Z; Chen L; Ye S; Huang J; Zhan J; Lin T
Br J Clin Pharmacol; 2011 Jun; 71(6):860-70. PubMed ID: 21276042
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance reversal by combretastatin-A4 phosphate loaded with doxorubicin in polymersomes independent of angiogenesis effect.
Zhu J; Hu M; Qiu L
J Pharm Pharmacol; 2017 Jul; 69(7):844-855. PubMed ID: 28425588
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, excretion, and distribution of combretastatin A4 phosphate in rats.
Xu XP; Wu XD; Liang GL; Huang WS; Wang L; Jing HY; Zhong SL
Pharmazie; 2012 Jun; 67(6):529-33. PubMed ID: 22822542
[TBL] [Abstract][Full Text] [Related]
15. Combretastatin A4 phosphate.
West CM; Price P
Anticancer Drugs; 2004 Mar; 15(3):179-87. PubMed ID: 15014350
[TBL] [Abstract][Full Text] [Related]
16. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.
Vincent L; Kermani P; Young LM; Cheng J; Zhang F; Shido K; Lam G; Bompais-Vincent H; Zhu Z; Hicklin DJ; Bohlen P; Chaplin DJ; May C; Rafii S
J Clin Invest; 2005 Nov; 115(11):2992-3006. PubMed ID: 16224539
[TBL] [Abstract][Full Text] [Related]
17. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats.
Liu Y; De Keyzer F; Wang Y; Wang F; Feng Y; Chen F; Yu J; Liu J; Song S; Swinnen J; Bormans G; Oyen R; Huang G; Ni Y
Int J Cancer; 2018 Oct; 143(7):1817-1828. PubMed ID: 29707770
[TBL] [Abstract][Full Text] [Related]
18. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
19. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation.
Nallamothu R; Wood GC; Pattillo CB; Scott RC; Kiani MF; Moore BM; Thoma LA
AAPS PharmSciTech; 2006 Apr; 7(2):E32. PubMed ID: 16796350
[TBL] [Abstract][Full Text] [Related]
20. Peripherally cross-linking the shell of core-shell polymer micelles decreases premature release of physically loaded combretastatin A4 in whole blood and increases its mean residence time and subsequent potency against primary murine breast tumors after IV administration.
Wakaskar RR; Bathena SP; Tallapaka SB; Ambardekar VV; Gautam N; Thakare R; Simet SM; Curran SM; Singh RK; Dong Y; Vetro JA
Pharm Res; 2015 Mar; 32(3):1028-44. PubMed ID: 25223962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
